MedTrace Logo

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

NCT00949624 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-01-19

No results posted yet for this study

Summary

A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and tolerability of adding targeted agents to a standard chemotherapy. CP-868,596 is a platelet-derived growth factor receptor inhibitor (PDGFR) and AG-13736 is a vascular endothelial growth factor receptor inhibitor (VEGFR). This study will test the use of docetaxel (the standard chemotherapy) with either CP-868,596 or the combination of CP-868,596 and AG-13736.

Conditions

Interventions

DRUG

CP-868,596

Oral tablet 60 mg BID continuous

DRUG

Docetaxel

Intravenous 75 mg/m2 every three weeks

DRUG

CP-868,596

Oral tablet 100 mg BID continuous

DRUG

Docetaxel

Intravenous 75 mg/m2 every three weeks

DRUG

CP-868,596

Oral tablet 100 mg BID continuous

DRUG

Docetaxel

Intravenous 100 mg/m2 every three weeks

DRUG

CP-868,596

Oral tablet 60 mg BID continuous

DRUG

AG-013736

Oral tablet 5 mg BID continuous

DRUG

Docetaxel

Intravenous 75 mg/m2 every three weeks

Sponsors & Collaborators

  • Arog Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949624 on ClinicalTrials.gov